Retrospective Analysis of the Clinical Efficacy, Safety, and Influencing Factors of Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Hepatic Malignancies.

IF 1.9 4区医学 Q3 ONCOLOGY

Clinical Medicine Insights-Oncology Pub Date : 2026-03-25 eCollection Date: 2026-01-01 DOI:10.1177/11795549261434259

Li Liu, Yuling Sheng, Xianxian Liang, Tao Yang, Li Dong, Dazhi Gao, Bo Chen, Tantan Xu, Min Ai, Husheng Shan, Jinjing Tang, Longjiang Zhang, Donghong Shi, Xiaoli Zhu

{"title":"Retrospective Analysis of the Clinical Efficacy, Safety, and Influencing Factors of Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Hepatic Malignancies.","authors":"Li Liu, Yuling Sheng, Xianxian Liang, Tao Yang, Li Dong, Dazhi Gao, Bo Chen, Tantan Xu, Min Ai, Husheng Shan, Jinjing Tang, Longjiang Zhang, Donghong Shi, Xiaoli Zhu","doi":"10.1177/11795549261434259","DOIUrl":null,"url":null,"abstract":"Background: Transarterial chemoembolization (TACE) is an established therapeutic modality for malignant hepatic tumors. This study assessed the clinical efficacy, adverse events, and factors associated with treatment outcomes of drug-eluting bead transarterial chemoembolization (DEB-TACE) in the treatment of hepatic malignancies.Methods: Clinical data were collected from 94 patients with hepatic malignancies who underwent DEB-TACE. Treatment response was assessed in accordance with the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Postoperative complications and relevant hematological parameters were analyzed by reviewing clinical symptoms and laboratory/examination findings. Logistic regression analysis was used to identify factors associated with treatment outcomes.Results: Median follow-up duration was 29.0 months (range: 3.0-51.0 months). Treatment response assessment post-DEB-TACE revealed that 2 patients (2.1%) achieved a complete response (CR), 53 (56.4%) achieved a partial response (PR), 27 (28.7%) had stable disease (SD), and 12 (12.8%) developed progressive disease (PD). The overall objective response rate (ORR) was 58.5%, and the disease control rate (DCR) was 87.2%. Median progression-free survival (PFS) was 5.0 months (95% confidence interval [CI]: 3.7-6.3 months), and median overall survival (OS) was 15.0 months (95% CI: 7.6-22.4 months). Multivariate logistic regression analysis demonstrated that hematological parameters-including D-dimer levels, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) levels-were associated with patient prognosis and survival outcomes.Conclusions: Drug-eluting bead transarterial chemoembolization is an effective treatment for various liver malignancies, associated with few manageable postoperative complications. In addition, d-dimer, the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) levels may predict DEB-TACE efficacy.","PeriodicalId":48591,"journal":{"name":"Clinical Medicine Insights-Oncology","volume":"20 ","pages":"11795549261434259"},"PeriodicalIF":1.9000,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13018707/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11795549261434259","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Transarterial chemoembolization (TACE) is an established therapeutic modality for malignant hepatic tumors. This study assessed the clinical efficacy, adverse events, and factors associated with treatment outcomes of drug-eluting bead transarterial chemoembolization (DEB-TACE) in the treatment of hepatic malignancies.

Methods: Clinical data were collected from 94 patients with hepatic malignancies who underwent DEB-TACE. Treatment response was assessed in accordance with the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Postoperative complications and relevant hematological parameters were analyzed by reviewing clinical symptoms and laboratory/examination findings. Logistic regression analysis was used to identify factors associated with treatment outcomes.

Results: Median follow-up duration was 29.0 months (range: 3.0-51.0 months). Treatment response assessment post-DEB-TACE revealed that 2 patients (2.1%) achieved a complete response (CR), 53 (56.4%) achieved a partial response (PR), 27 (28.7%) had stable disease (SD), and 12 (12.8%) developed progressive disease (PD). The overall objective response rate (ORR) was 58.5%, and the disease control rate (DCR) was 87.2%. Median progression-free survival (PFS) was 5.0 months (95% confidence interval [CI]: 3.7-6.3 months), and median overall survival (OS) was 15.0 months (95% CI: 7.6-22.4 months). Multivariate logistic regression analysis demonstrated that hematological parameters-including D-dimer levels, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) levels-were associated with patient prognosis and survival outcomes.

Conclusions: Drug-eluting bead transarterial chemoembolization is an effective treatment for various liver malignancies, associated with few manageable postoperative complications. In addition, d-dimer, the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) levels may predict DEB-TACE efficacy.

查看原文本刊更多论文

药物洗脱珠经动脉化疗栓塞治疗不可切除肝脏恶性肿瘤的临床疗效、安全性及影响因素回顾性分析。

背景：经动脉化疗栓塞（TACE）是一种成熟的治疗恶性肝脏肿瘤的方法。本研究评估了药物洗脱经动脉化疗栓塞（DEB-TACE）治疗肝脏恶性肿瘤的临床疗效、不良事件和相关因素。方法：收集94例肝脏恶性肿瘤行DEB-TACE的临床资料。根据修订的实体瘤反应评价标准（mRECIST）评估治疗反应。通过回顾临床症状和实验室/检查结果，分析术后并发症和相关血液学参数。采用Logistic回归分析确定与治疗结果相关的因素。结果：中位随访时间为29.0个月（范围：3.0-51.0个月）。deb - tace后的治疗反应评估显示，2例（2.1%）患者达到完全缓解（CR）， 53例（56.4%）患者达到部分缓解（PR）， 27例（28.7%）患者病情稳定（SD）， 12例（12.8%）患者病情进展（PD）。总客观有效率（ORR）为58.5%，疾病控制率（DCR）为87.2%。中位无进展生存期（PFS）为5.0个月（95%可信区间[CI]: 3.7-6.3个月），中位总生存期（OS）为15.0个月（95% CI: 7.6-22.4个月）。多因素logistic回归分析表明，血液学参数——包括d -二聚体水平、中性粒细胞与淋巴细胞比率（NLR）、血小板与淋巴细胞比率（PLR）和c反应蛋白（CRP）水平——与患者预后和生存结果相关。结论：药物洗脱经动脉化疗栓塞是治疗多种肝脏恶性肿瘤的有效方法，且术后并发症少。此外，d-二聚体、中性粒细胞与淋巴细胞比率（NLR）、血小板与淋巴细胞比率（PLR）和c反应蛋白（CRP）水平可以预测DEB-TACE的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Medicine Insights-Oncology Medicine-Oncology

CiteScore

2.40

自引率

4.50%

发文量

审稿时长

8 weeks

期刊介绍： Clinical Medicine Insights: Oncology is an international, peer-reviewed, open access journal that focuses on all aspects of cancer research and treatment, in addition to related genetic, pathophysiological and epidemiological topics. Of particular but not exclusive importance are molecular biology, clinical interventions, controlled trials, therapeutics, pharmacology and drug delivery, and techniques of cancer surgery. The journal welcomes unsolicited article proposals.